Ken Griffin Cytek Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 600 shares of CTKB stock, worth $1,608. This represents 0.0% of its overall portfolio holdings.
Number of Shares
600
Previous 1,000
40.0%
Holding current value
$1,608
Previous $6,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CTKB
# of Institutions
159Shares Held
73.8MCall Options Held
600Put Options Held
4.9K-
Black Rock Inc. New York, NY17.1MShares$45.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.62MShares$25.8 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD7.46MShares$20 Million0.93% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$17.8 Million0.82% of portfolio
-
State Street Corp Boston, MA4.38MShares$11.7 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $361M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...